(Q41785872)

9 October 2017

The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer (English)

1 reference

9 October 2017

0 references

1

1 reference

9 October 2017

Claire Vanpouille-Box

series ordinal

2

1 reference

9 October 2017

Sylvia Adams

4

0 references

Silvia C. Formenti

series ordinal

3

object named as

Silvia C Formenti

1 reference

9 October 2017

24 September 2013

1 reference

9 October 2017

1 reference

9 October 2017

2

1 reference

9 October 2017

10

1 reference

9 October 2017

e25997

1 reference

Combining radiotherapy and cancer immunotherapy: a paradigm shift

9 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3881106

Synergy of topical toll-like receptor 7 agonist with radiation and low-dose cyclophosphamide in a mouse model of cutaneous breast cancer

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3881106

Suppressing T cell motility induced by anti-CTLA-4 monotherapy improves antitumor effects

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3881106

Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3881106

Toll-like receptor agonists in cancer therapy

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3881106

Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3881106

Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3881106

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3881106

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3881106

Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3881106

18 August 2018

Identifiers

DOI

10.4161/ONCI.25997

1 reference

release_7ul3skbyz5grbc2qgsp7eeevbm

9 October 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/7ul3skbyz5grbc2qgsp7eeevbm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

9 October 2017

PubMed publication ID

24404422

1 reference